Use of autologous serum eye drops for the dry and inflammed eye i | 52107
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

Use of autologous serum eye drops for the dry and inflammed eye in severe ocular graft versus host disease

lnternational Conference on Eye Disorders and Treatment

July 13-15, 2015 Baltimore, USA

Datiles M, Pavletic S, Bishop R, Garced A, Clayton J, May J, Mitchell S, Cowen E, Williams K, Fowler D, Childs, R, Barrett J, Battiwala M, Grimes G, Starling J. Pomerenke S, Cantilena C and Ferris FL

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Recently, hematopoetic stem cell transplant (formerly called Bone Marrow Transplant) has become an increasingly successful treatment not only for blood cancers but also for auto immune disorders and solid organ cancers. However, the main long term side effect is chronic graft versus host disease, wherein the donor t-cells are dysregulated and cause varying degrees of inflammation and scar formation in various tissues in the body, including eye and skin. In most cases,the inflammation is successfully controlled by steroids and anti T cell treatments. However, some patients experience severe GVHD which respond poorly to steroids and other treatments. We are currently conducting an FDA approved randomized double masked placebo controlled clinical trial of Autologous serum eye drops for severe ocular graft versus host disease in hematopoetic stem cell transplant. We would like to share experiences in developing the clinical protocol including various clinical tests of the ocular surface of the eye and dry eye questionnaires, and dealing with problems associated with drawing blood in these very ill patients as well as a preliminary analysis of data.

Biography :

Datiles M currently sees eye patients as part of clinical trials and research studies at NIH, including an ongoing study of ocular graft-versus-host disease in recipients of adult stem cell transplants. His long-term research focuses on cataract development and clinical trials involving anti-cataract drugs. He also collaborates with NEI lens researchers to study the genetic causes of cataracts, and with Johns Hopkins University researchers to study the aggregation of lens proteins, which may lead to cataract development. He is the author of more than one hundred scientific manuscripts and textbook chapters. He has also served as an ad hoc editorial board member and reviewer for major ophthalmology journals, including Archives of Ophthalmology, Ophthalmology and Investigative Ophthalmology & Visual Science.